Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
- 1 November 2014
- journal article
- research article
- Published by Elsevier BV in Bone
- Vol. 68, 115-123
- https://doi.org/10.1016/j.bone.2014.08.010
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Rosiglitazone and Outcomes for Patients With Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) TrialCirculation, 2013
- Risk of fracture with thiazolidinediones: an individual patient data meta-analysisFrontiers in Endocrinology, 2013
- Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III StudyDementia and Geriatric Cognitive Disorders, 2010
- The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Increases Bone Resorption in Women with Type 2 Diabetes: A Randomized, Controlled TrialCalcified Tissue International, 2010
- Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes MellitusJournal of Clinical Endocrinology & Metabolism, 2010
- The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series StudyPLoS Medicine, 2009
- Thiazolidinedione use and the risk of fracturesCMAJ : Canadian Medical Association Journal, 2009
- Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysisCMAJ : Canadian Medical Association Journal, 2009
- Measuring inconsistency in meta-analysesBMJ, 2003